SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

10 Nov 2022 Evaluate
A fair growth of 11.92% in the revenue at Rs. 4326.90 millions was reported in the September 2022 quarter as compared to Rs. 3865.90 millions during year-ago period.The Company has registered profit of Rs. 496.40  millions for the quarter ended September 2022, a growth of 19.41%  over Rs. 415.70 millions millions achieved in the corresponding quarter of last year.Operating Profit saw a handsome growth to 881.00 millions from 873.30 millions in the quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 4326.90 3865.90 11.92 8405.90 7730.80 8.73 15397.20 12403.00 24.14
Other Income 3.40 10.10 -66.34 14.70 18.70 -21.39 23.20 31.20 -25.64
PBIDT 881.00 873.30 0.88 1605.30 1750.00 -8.27 3293.20 2266.90 45.27
Interest 52.50 30.60 71.57 93.80 72.90 28.67 141.40 222.20 -36.36
PBDT 828.50 842.70 -1.69 1511.50 1677.10 -9.87 3151.80 2044.70 54.14
Depreciation 156.50 194.60 -19.58 357.50 416.90 -14.25 789.50 731.20 7.97
PBT 672.00 648.10 3.69 1154.00 1260.20 -8.43 2362.30 1313.50 79.85
TAX 175.60 232.40 -24.44 272.90 448.40 -39.14 817.10 389.60 109.73
Deferred Tax -16.80 -30.80 -45.45 -73.50 -88.40 -16.86 -115.20 4.90 -2451.02
PAT 496.40 415.70 19.41 881.10 811.80 8.54 1545.20 923.90 67.25
Equity 184.30 184.30 0.00 184.30 184.30 0.00 184.30 184.30 0.00
PBIDTM(%) 20.36 22.59 -9.87 19.10 22.64 -15.64 21.39 18.28 17.02

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×